Problems of vaccination and ways to optimize it: a review of randomized clinical trials evaluating Anaferon for children

Q4 Medicine

Infektsionnye Bolezni Pub Date : 2021-01-01 DOI:10.20953/1729-9225-2021-3-116-122

A. Zaplatnikov, E. Kondyurina

{"title":"Problems of vaccination and ways to optimize it: a review of randomized clinical trials evaluating Anaferon for children","authors":"A. Zaplatnikov, E. Kondyurina","doi":"10.20953/1729-9225-2021-3-116-122","DOIUrl":null,"url":null,"abstract":"In this article, we discuss the problem of improving vaccination efficacy in children using an antiviral drug with an immunomodulatory effect Anaferon for children produced in Russia. We analyzed the results of randomized clinical trials (RCTs) evaluating the efficacy and safety of Anaferon for children during vaccination against influenza and pneumococcal infection, including that in children with frequent respiratory infections. According to RCT, Anaferon for children used for the prevention of acute respiratory viral infections (ARVI) in combination with specific immunoprophylaxis of influenza and pneumococcal infection, increased the vaccination coverage by reducing the frequency of ARVI episodes before vaccination period and facilitating the development of an adequate immune response after vaccination. Anaferon for children also demonstrated a good safety profile. We described the schemes of ARVI/influenza prevention: 1 tablet a day for 2–4 weeks before vaccination with possible continuation after vaccination for up to 3 months, depending on the clinical situation during the development of active immunity. The results of RCTs and many years of experience allow us to recommend Anaferon for children combination with specific immunoprophylaxis to optimize the vaccination campaign, especially in children with low resistance to infections. It is particularly important during the pandemic of new coronavirus infection. Key words: vaccination, Anaferon for children, prevention, acute respiratory viral infections","PeriodicalId":37794,"journal":{"name":"Infektsionnye Bolezni","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infektsionnye Bolezni","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20953/1729-9225-2021-3-116-122","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

In this article, we discuss the problem of improving vaccination efficacy in children using an antiviral drug with an immunomodulatory effect Anaferon for children produced in Russia. We analyzed the results of randomized clinical trials (RCTs) evaluating the efficacy and safety of Anaferon for children during vaccination against influenza and pneumococcal infection, including that in children with frequent respiratory infections. According to RCT, Anaferon for children used for the prevention of acute respiratory viral infections (ARVI) in combination with specific immunoprophylaxis of influenza and pneumococcal infection, increased the vaccination coverage by reducing the frequency of ARVI episodes before vaccination period and facilitating the development of an adequate immune response after vaccination. Anaferon for children also demonstrated a good safety profile. We described the schemes of ARVI/influenza prevention: 1 tablet a day for 2–4 weeks before vaccination with possible continuation after vaccination for up to 3 months, depending on the clinical situation during the development of active immunity. The results of RCTs and many years of experience allow us to recommend Anaferon for children combination with specific immunoprophylaxis to optimize the vaccination campaign, especially in children with low resistance to infections. It is particularly important during the pandemic of new coronavirus infection. Key words: vaccination, Anaferon for children, prevention, acute respiratory viral infections

查看原文本刊更多论文

疫苗接种的问题和优化方法:评价儿童安那菲龙的随机临床试验综述

在这篇文章中，我们讨论了使用俄罗斯生产的具有免疫调节作用的儿童抗病毒药物Anaferon来提高儿童疫苗接种效果的问题。我们分析了随机临床试验(RCTs)的结果，这些试验评估了儿童在接种流感和肺炎球菌感染疫苗期间，包括经常呼吸道感染的儿童，使用Anaferon的有效性和安全性。根据随机对照试验，用于预防急性呼吸道病毒感染(ARVI)的儿童Anaferon与流感和肺炎球菌感染的特异性免疫预防相结合，通过减少疫苗接种期前ARVI发作的频率和促进疫苗接种后充分免疫反应的发展，提高了疫苗接种覆盖率。儿童用Anaferon也显示出良好的安全性。我们描述了ARVI/流感预防方案:接种疫苗前2-4周每天1片，接种后可能持续3个月，这取决于主动免疫发展期间的临床情况。随机对照试验的结果和多年的经验使我们能够推荐Anaferon与特异性免疫预防联合用于儿童，以优化疫苗接种运动，特别是对感染抵抗力低的儿童。在新型冠状病毒大流行期间，这一点尤为重要。关键词:疫苗接种，儿童安那芬，预防，急性呼吸道病毒感染

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infektsionnye Bolezni Medicine-Infectious Diseases

CiteScore

1.30

自引率

0.00%

发文量

期刊介绍： The journal publishes original research works, reviews of literature, lectures, methodological recommendations, clinical observations. Main topics: problems of etiology, pathogenesis, clinical manifestations of infectious diseases, new techniques and methods of their diagnosis, prevention and treatment; special attention is paid to the problems of antibacterial and antiviral therapy, the use of immunoglobulins and interferons, and also to intensive therapy of critical states. The journal is in the List of leading scientific journals and periodicals of the Supreme Attestation Committee, where the principal results of doctoral dissertations should be published.